Phase II trial of 9-nitrocamptothecin (RFS 2000) for patients with metastatic cutaneous or uveal melanoma

Anti-Cancer Drugs

Volumn 13, Issue 2, 2002, Pages 169-172

  Ellerhorst, Julie A ^a   Bedikian, Agop Y ^a   Smith, Teresa M ^a   Papadopoulos, Nicholas E ^a   Plager, Carl ^a   Eton, Omar ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

9 Nitrocamptothecin; Camptothecin; Cutaneous melanoma; RFS 2000; Uveal melanoma

Indexed keywords

CAMPTOTHECIN; RUBITECAN;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; CHEMICAL CYSTITIS; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; FEMALE; GASTROINTESTINAL SYMPTOM; HEMATURIA; HUMAN; MALE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SKIN METASTASIS; UVEA MELANOMA; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; DIARRHEA; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; NEUTROPENIA; SKIN NEOPLASMS; TREATMENT OUTCOME; UVEAL NEOPLASMS;

EID: 0036185945     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200202000-00009     Document Type: Article

References (16)

1. Systemic treatments for advanced cutaneous melanoma
2. Uveal melanoma: Natural history and treatment options for metastatic disease
3. Action of camptothecin on mammalian cells in culture
4. Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin
5. Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase I: Evidence for a specific receptor site and a relation to antitumor activity
6. A phase I clinical and pharmacokinetic study of oral 9-nitrocamptothecin, a novel water insoluble topoisomrase I inhibitor
7. A phase II clinical and pharmacological study of oral 9-nitrocamptothecin in patients with refractory epithelial ovarian, tubal or peritoneal cancer
8. A study of 9-nitrocamptothecin (RFS-2000) in patients with advanced pancreatic cancer
9. Cytotoxic efficacy of 9-nitrocamptothecin in the treatment of human malignant melanoma cells in vitro
10. Complete inhibition of growth followed by death of human malignant melanoma cells in vitro and regression of human melanoma xenografts in immunodeficient mice induced by camptothecins
11. 9-Nitrocamptothecin liposome aerosol treatment of melanoma and osteosarcoma lung metastases in mice
12. Optimal two-stage designs for phase II clinical trials
13. Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC-100880)
14. Treatment of malignant melanoma with camptothecin (NSC-100880)
15. Phase II trial of topotecan in malignant melanoma
16. A prospective randomized phase II trial of GM-CSF priming to prevent topotecan-induced neutropenia in chemotherapy-naive patients with malignant melanoma or renal cell carcinoma